Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device Remplirâ„¢, with clearance expected in Q3 CY2025.
This is an important milestone in our global expansion plans for Remplirâ„¢, with the Thailand nerve repair market representing an $84M opportunity.
Remplir is now gaining record sales traction in Australia, New Zealand and Singapore, with all sights set on US FDA clearance in March/April 2025.